MIST
Milestone Pharmaceuticals Inc.
Next earnings Aug 10, 2026 · consensus $-0.20 EPS, $1.12M rev
Last earnings -9.5% on 2026-05-13
$1.24
▼ -0.80%$1.24▼ -29.55%
over 1Y
L $1.01EODHDH $2.95
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-0.8%
1W-5.3%
1M-11.4%
3M+19.2%
YTD-39.5%
1Y-29.5%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Buy
Mixed signals in the latest filings.
Return on equity -151.0% · latest
Milestone Pharmaceuticals Inc. shows limited reported revenue, and -151.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$43.1M | -$59.6M | -$61.1M | -$42.1M | -$62.1M |
| Net income | -$42.9M | -$58.4M | -$59.7M | -$41.5M | -$63.1M |
| Diluted EPS | -$1.02 | -$1.38 | -$1.39 | -$0.67 | -$0.75 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$130M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-43.2%
FCF yield-33.8%
Quality & risk
ROIC (est.)-49.6%
Free cash flow-$49.3M
Total debt$57.2M
Net cash$15.9M
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+120.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-102026-06-15open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗EFFECTFiling2026-05-22open ↗SCHEDULE 13G/AFiling2026-05-15open ↗S-3Filing2026-05-13open ↗SCHEDULE 13G/AFiling2026-05-13open ↗
Frequently asked
- Is Milestone Pharmaceuticals Inc. (MIST) a buy?
- MIST currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
- What is Milestone Pharmaceuticals Inc.'s quality score?
- MIST scores 32.38461538461539/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001408443, latest 10-Q filed 2026-05-13) · EODHD · as of 6/26/2026, 5:58:37 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.